BACKGROUND: Diabetes is a chronic, potentially debilitating, and often fatal disease. Dietary strategies to reduce postprandial glycemia are important in the prevention and treatment of diabetes. Nuts are rich in mono- and polyunsaturated fatty acids, which may reduce hyperglycemia and improve metabolism. OBJECTIVES: To evaluate the effectiveness of pistachio nut supplementation on glycemic and inflammatory measures in patients with type 2 diabetes. METHODS: In this double-blind, randomized, placebo-controlled, crossover trial, 48 diabetic patients were equally assigned to groups A and B. Patients in group A received a snack of 25 g pistachio nuts twice a day for 12 weeks and group B received a control meal without nuts. After 12 weeks of intervention, the patients had an 8-week washout. Then the groups were displaced, and group B received the same amount of pistachios for 12 weeks. RESULTS: With respect to the total change in variables over both phases, there was a marked decrease in HbA1c (-0.4%) and fasting blood glucose (FBG) concentrations (-16 mg/dl) in the pistachio group compared with the control group (p ≤ 0.001 for both). There was no overall significant change in BMI, blood pressure, HOMA-IR, and C-reactive protein (CRP) concentrations. Analysis of the two phases separately showed a decrease in FBG by 14 mg/dl and in HbA1c by 0.45% in the treatment group (A) after 12 weeks, while no significant differences were seen in group B (control group). In the second phase, FBG decreased from 151.36 ± 39.22 to 137.28 ± 28.65 mg/dl (-14 mg/dl) and HbA1c decreased from 7.42 ± 0.97 to 7.15 ± 0.68 mg/dl (-0.28%, p = 0.013 and p = 0.033, respectively) in the pistachio group (B). Pistachio consumption reduced systolic blood pressure (p = 0.007), BMI (p = 0.011), and CRP (p = 0.002) in patients from the treatment groups, but not insulin resistance. CONCLUSIONS: Dietary consumption of pistachio nuts as a snack has beneficial effects on glycemic control, blood pressure, obesity, and inflammation markers in diabetic patients.
RCT Entities:
BACKGROUND:Diabetes is a chronic, potentially debilitating, and often fatal disease. Dietary strategies to reduce postprandial glycemia are important in the prevention and treatment of diabetes. Nuts are rich in mono- and polyunsaturated fatty acids, which may reduce hyperglycemia and improve metabolism. OBJECTIVES: To evaluate the effectiveness of pistachio nut supplementation on glycemic and inflammatory measures in patients with type 2 diabetes. METHODS: In this double-blind, randomized, placebo-controlled, crossover trial, 48 diabeticpatients were equally assigned to groups A and B. Patients in group A received a snack of 25 g pistachio nuts twice a day for 12 weeks and group B received a control meal without nuts. After 12 weeks of intervention, the patients had an 8-week washout. Then the groups were displaced, and group B received the same amount of pistachios for 12 weeks. RESULTS: With respect to the total change in variables over both phases, there was a marked decrease in HbA1c (-0.4%) and fasting blood glucose (FBG) concentrations (-16 mg/dl) in the pistachio group compared with the control group (p ≤ 0.001 for both). There was no overall significant change in BMI, blood pressure, HOMA-IR, and C-reactive protein (CRP) concentrations. Analysis of the two phases separately showed a decrease in FBG by 14 mg/dl and in HbA1c by 0.45% in the treatment group (A) after 12 weeks, while no significant differences were seen in group B (control group). In the second phase, FBG decreased from 151.36 ± 39.22 to 137.28 ± 28.65 mg/dl (-14 mg/dl) and HbA1c decreased from 7.42 ± 0.97 to 7.15 ± 0.68 mg/dl (-0.28%, p = 0.013 and p = 0.033, respectively) in the pistachio group (B). Pistachio consumption reduced systolic blood pressure (p = 0.007), BMI (p = 0.011), and CRP (p = 0.002) in patients from the treatment groups, but not insulin resistance. CONCLUSIONS: Dietary consumption of pistachio nuts as a snack has beneficial effects on glycemic control, blood pressure, obesity, and inflammation markers in diabeticpatients.
Authors: Eoin O'Brien; Roland Asmar; Lawrie Beilin; Yutaka Imai; Giuseppe Mancia; Thomas Mengden; Martin Myers; Paul Padfield; Paolo Palatini; Gianfranco Parati; Thomas Pickering; Josep Redon; Jan Staessen; George Stergiou; Paolo Verdecchia Journal: J Hypertens Date: 2005-04 Impact factor: 4.844
Authors: Andrea R Josse; Cyril W C Kendall; Livia S A Augustin; Peter R Ellis; David J A Jenkins Journal: Metabolism Date: 2007-03 Impact factor: 8.694
Authors: C W C Kendall; S G West; L S Augustin; A Esfahani; E Vidgen; B Bashyam; K A Sauder; J Campbell; L Chiavaroli; A L Jenkins; D J Jenkins Journal: Eur J Clin Nutr Date: 2014-01-15 Impact factor: 4.016
Authors: Jennifer C Lovejoy; Marlene M Most; Michael Lefevre; Frank L Greenway; Jennifer C Rood Journal: Am J Clin Nutr Date: 2002-11 Impact factor: 7.045
Authors: Bonnie J Brehm; Barbara L Lattin; Suzanne S Summer; Jane A Boback; Gina M Gilchrist; Ronald J Jandacek; David A D'Alessio Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112
Authors: Gang Liu; Marta Guasch-Ferré; Yang Hu; Yanping Li; Frank B Hu; Eric B Rimm; JoAnn E Manson; Kathryn M Rexrode; Qi Sun Journal: Circ Res Date: 2019-03-15 Impact factor: 17.367
Authors: Atena Mahdavi; Mohammad Bagherniya; Mohammad Sadegh Mirenayat; Stephen L Atkin; Amirhossein Sahebkar Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Stephanie K Nishi; Effie Viguiliouk; Sonia Blanco Mejia; Cyril W C Kendall; Richard P Bazinet; Anthony J Hanley; Elena M Comelli; Jordi Salas Salvadó; David J A Jenkins; John L Sievenpiper Journal: Obes Rev Date: 2021-09-08 Impact factor: 10.867
Authors: Katherine A Sauder; Cindy E McCrea; Jan S Ulbrecht; Penny M Kris-Etherton; Sheila G West Journal: Metabolism Date: 2015-07-30 Impact factor: 8.694